Bevacizumab, a vascular endothelial growth factor (VEGF) antagonist, commercially known as Avastin, suppresses angiogenesis thereby prolonging survival of metastatic CRC patients when combined with chemotherapy [5]. The gene discussed is VEGFA; the disease is colorectal carcinoma.